Trimipramine (trimipramine maleate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Trimipramine maleate is a dibenzazepine-derivative tricyclic antidepressant.
Trimipramine maleate shares the pharmacologic actions of the other tricyclic antidepressants and is used primarily in the treatment of endogenous depression. Studies comparing trimipramine with amitriptyline or imipramine have not demonstrated superiority of trimipramine over these other tricyclic antidepressants.
Generic name: trimipramine maleate
Pronunciation: (trye-MI-pra-meen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Trimipramine
Indications
The following indications are listed for Trimipramine:
- Depression
Also known as: Depressed Mood, Depressive Disorder, Depressive Reaction, Depressive Syndrome, Mental Depression.
Dosing
Dosage of trimipramine maleate is expressed in terms of trimipramine. There is a wide range of dosage requirements, and dosage must be carefully individualized. Initial dosages should be low and generally range from 75-100 mg daily. Dosage may be gradually adjusted to the level that produces maximal therapeutic effect with minimal toxicity and may range up to 300 mg daily. Hospitalized patients under close supervision may generally be given higher dosages than outpatients, and the manufacturer states that dosages greater than 200 mg daily are not recommended for outpatients. Geriatric and adolescent patients should usually be given lower than average dosages. The manufacturer states that therapy should be initiated with 50 mg daily in these patients and the optimal dosage rarely exceeds 100 mg daily. Maximum antidepressant effects may not occur for 2 or more weeks after therapy is begun.
After symptoms are controlled, dosage should be gradually reduced to the lowest level which will maintain relief of symptoms. If maintenance therapy is necessary, the manufacturer recommends 50-150 mg daily, preferably administered as a single daily dose at bedtime. Maintenance therapy should be continued for at least 3 months to prevent relapse.
Patients should be monitored for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment. (See Cautions: Precautions and Contraindications, in the Tricyclic Antidepressants General Statement 28:16.04.28.)
Trimipramine maleate is administered orally. Although trimipramine maleate has been administered in up to 4 divided doses throughout the day, it is long-acting and, when daily dosage does not exceed 200 mg, the entire daily dose may be administered at one time. Administration of most or all of the daily dosage at bedtime may reduce daytime sedation.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.